title: Inhibition of cerebral metabolic and circulatory responses to nitrous oxide by 6-hydroxydopamine in dogs.
abstract: OBJECTIVE
  To determine whether cerebral metabolic and circulatory consequences of N2O result from activation of the sympathoadrenal system. The effects of pretreatment with intracisternal injection of 6-OHDA, which produces chemical sympathectomy, were studied in dogs.
  
  
  METHODS
  Seven days before measurement dogs were pretreated with intracisternal injection of either saline vehicle (sham-group) or 100 micrograms.kg-1 6-hydroxydopamine (6-OHDA, group). Cerebral blood flow (CBF) was measured using an electromagnetic flow-meter probe and cerebral metabolic rate for oxygen (CMRO2) was calculated as the product of CBF and arterial-sagittal sinus blood oxygen content difference [C(a-v)O2].
  
  
  RESULTS
  In the sham group, N2O (60%) increased CMRO2 from 6.11 +/- 0.21 ml.100 g-1.min-1 to 7.10 +/- 0.39 ml.100 g-1.min-1 and CBF from 63 +/- 5 ml.100 g-1.min-1 to 173 +/- 26 ml.100 g-1.min-1. In the 6-OHDA group, CMRO2, did not change during N2O exposure, whereas CBF increased from 61 +/- 3 ml.100 g-1.min-1 to 135 +/- 19 ml.100 g-1.min-1 but less then in the sham group. The 6-OHDA group displayed a reduction in cortical noradrenaline (NA) concentration from 263.2 +/- 35.6 ng.g-1 to 102.7 +/- 16.5 ng.g-1. Cortical dopamine (DA) concentration was not affected by 6-OHDA administration.
  
  
  CONCLUSIONS
  These results suggest that most of the increase in CMRO2 and at least a part of the increase in CBF during N2O exposure in the sham-group are related to sympathoadrenal-stimulating effects of N2O.
authors.affiliation: Department of Dental Anesthesiology, kyushu Dental College, Kitakyushu, Japan. nakanisi@kyu-dent.ac.jp
authors.forename: O
authors.initials: O
authors.lastname: Nakanishi
authors.forename: T
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Imamura
authors.forename: T
authors.initials: T
authors.lastname: Hirakawa
mesh_terms: D018663:Adrenergic Agents / Q000494:pharmacology*; D018685:Anesthetics, Inhalation / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002946:Cisterna Magna; D003392:Cranial Sinuses; D004285:Dogs; D004298:Dopamine / Q000378:metabolism; D055590:Electromagnetic Phenomena; D005260:Female; D007267:Injections; D008297:Male; D009609:Nitrous Oxide / Q000494:pharmacology*; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000378:metabolism; D016627:Oxidopamine / Q000494:pharmacology*; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects; D012212:Rheology; D013563:Sympathectomy, Chemical; D013565:Sympatholytics / Q000494:pharmacology*
chemical_list: D018663:Adrenergic Agents; D018685:Anesthetics, Inhalation; D013565:Sympatholytics; D016627:Oxidopamine; D009609:Nitrous Oxide; D010100:Oxygen; D004298:Dopamine; D009638:Norepinephrine